<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653131</url>
  </required_header>
  <id_info>
    <org_study_id>GLP-1</org_study_id>
    <nct_id>NCT02653131</nct_id>
  </id_info>
  <brief_title>The Use of DPP-4 Inhibitors in Short Bowel Syndrome</brief_title>
  <acronym>DPP-4</acronym>
  <official_title>The Use of Dipeptidyl Peptidase-4 Inhibitor Influences the Absorption of Intestine in Short Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanley Dudrick's Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanley Dudrick's Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like
      peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of
      the intestine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The only effective (to some extend drug) in short bowel syndrome is Glucacone-like peptide 4.
      Its price is, however, to high to really change the treatment strategy for intestinal
      failure. The Dipeptidyl peptidase-4 inhibitor, which a drug which is commonly used in the
      treatment of diabetes mellitus type II, should increase the concentration of glucagone-like
      peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of
      the intestine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of intestinal absorption</measure>
    <time_frame>12 months</time_frame>
    <description>the use of DPP-4 inhibitor results in the better intestinal absorption</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>DPP-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The administration of the DPP-4 inhibitor in the form of a pill once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO DPP</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipeptidyl peptidase-4 inhibitor</intervention_name>
    <arm_group_label>DPP-4</arm_group_label>
    <other_name>Sitagliptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for
             at least 12 months

          -  stable metabolic status

          -  benign disease

        Exclusion Criteria:

          -  HPN &lt; 12 months

          -  metabolically unstable

          -  cancer as the reason for intestinal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stanislaw Klek, MD, PhD</last_name>
    <phone>604293566</phone>
    <phone_ext>+48</phone_ext>
    <email>klek@poczta.onet.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kinga Szczepanek, MD</last_name>
    <phone>608515670</phone>
    <email>kingaszm@interia.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanley Dudrick's Memorial Hospital</name>
      <address>
        <city>Skawina</city>
        <zip>32-050</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanislaw Klek, Assoc. Prof.</last_name>
      <phone>+48604293566</phone>
      <email>klek@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Stanislaw Klek, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Jeppesen PB. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2014 May;38(1 Suppl):45S-52S. doi: 10.1177/0148607114526241. Epub 2014 Mar 10. Review.</citation>
    <PMID>24615689</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2016</study_first_submitted>
  <study_first_submitted_qc>January 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanley Dudrick's Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Stanislaw Klek</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <keyword>Short bowel syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Short Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All data is a part of a research</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

